Lung Density Analysis vs ElucidVivo A.3
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Both IMBIO's Lung Density Analysis and ElucidVivo A.3 are FDA-cleared AI-powered medical imaging software providing quantitative analysis and 3D visualization from CT scans. However, they address distinct clinical needs: Lung Density Analysis focuses on pulmonary conditions like COPD and emphysema, while ElucidVivo A.3 specializes in the quantitative analysis of arterial plaque for atherosclerosis management. Therefore, they are adjacent tools serving different diagnostic areas within radiology and cardiology.
Choose Lung Density Analysis if…
Choose IMBIO's Lung Density Analysis if your primary focus is on comprehensive, AI-driven quantitative analysis and 3D visualization of lung parenchyma from CT scans. This tool is ideal for diagnosing and managing conditions like COPD and emphysema, especially when detailed insights into lung density, air-trapping, and emphysema quantification are critical for patient care and smoking cessation counseling.
View Lung Density Analysis →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 by Elucid Bioimaging if your objective is to perform advanced, quantitative analysis of arterial plaque composition and stability from CT angiography. This system is best suited for stratifying patients with atherosclerosis and optimizing cardiovascular treatment decisions, particularly when detailed visualization and measurement of plaque characteristics, validated against histology, are essential for risk assessment.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Lung Density Analysis | ElucidVivo A.3 |
|---|---|---|
| Deployment | Unknown | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Lung Density Analysis | ElucidVivo A.3 |
|---|---|---|
| Name | Lung Density Analysis | ElucidVivo A.3 |
| Company | IMBIO | Elucid Bioimaging |
| Primary Focus | Quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. | Quantitative analysis of arterial plaque composition and stability from CT angiography, assisting physicians in atherosclerosis patient stratification and optimizing treatment decisions. |
| Specific Analysis/Quantification | Automated detection, visualization, and quantification of emphysema; Mapping of normal lung, air-trapping, and emphysema (Functional LDA); Advanced density analysis for COPD, Asthma, BOS. | AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. |
| Visualization Capabilities | 3D visualization of lung conditions; Quantitative reports with coronal, axial, sagittal visuals and bar charts. | Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections. |
| Validated Against | Validated for low-dose CT scans in lung cancer screening. | Validated on ground-truth histology. |
Videos
Demos, reviews, and walkthroughs featuring Lung Density Analysis and ElucidVivo A.3.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
IMBIO's Lung Density Analysis offers automated workflows and fully automated quantitative analysis and 3D visualization directly to PACS, aiming for seamless integration into existing imaging systems. ElucidVivo A.3 is designed to integrate with PACS/EMR systems, providing quantitative analysis of arterial plaque composition and stability for cardiovascular care, and its user interface follows typical clinical workflow patterns.
IMBIO's Lung Density Analysis is validated for low-dose CT scans in lung cancer screening and utilizes Imbio Noise Reduction Technology (NRT) to enhance accuracy on such scans. ElucidVivo A.3's quantitative analysis of arterial plaque composition and stability is validated against ground-truth histology, providing a high level of confidence in its measurements.
Lung Density Analysis is uniquely suited for patients with COPD, emphysema, asthma, and BOS, as well as for lung cancer screening and smoking cessation counseling through its detailed LungMapu2122 report. ElucidVivo A.3 is specifically designed for stratifying patients with atherosclerosis by objectively quantifying plaque characteristics like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT angiography.
With its automated detection, visualization, and quantification features, Lung Density Analysis is designed to streamline analysis, potentially reducing the learning curve for physicians and staff. This automation can contribute to a quicker realization of value in managing lung conditions. ElucidVivo A.3 provides AI-powered quantitative analysis and 3D visualization of plaque, which can offer immediate objective measurements for atherosclerosis patient stratification and optimizing treatment decisions.
The provided information does not explicitly detail specific audit-trail features for Lung Density Analysis. Physicians would need to inquire directly with IMBIO for specifics on how analysis, user actions, and data modifications are tracked. Similarly, the description for ElucidVivo A.3 does not explicitly mention its audit-trail functionalities, requiring further inquiry with Elucid Bioimaging to understand how analysis, user actions, and data modifications are logged.
Lung Density Analysis offers flexible deployment options including cloud-based, locally virtualized, and integration into PACS or AI marketplaces, which can simplify multi-site rollout and management. ElucidVivo A.3, as a software application designed to integrate with PACS/EMR, would require careful planning for consistent deployment and data flow across multiple sites, whether deployed on-premise or cloud-based.